Q1 2027 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Key Points
- Successfully completed MFDS Korea inspection at Naroda site, underscoring commitment to quality compliance.
- Secured two new CEPs in Europe and drug product approvals in Myanmar, expanding regulatory footprint.
- Signed a commercial contract for tech transfer from Switzerland to India, with a second major project approved by a Swiss MNC.
- Vitamin D and analogues business saw increased sales and margins, with access to new suppliers at attractive prices.
- New commercial product from a big pharma approved by US FDA, adding to portfolio; more than 13 late-phase projects including PPQ campaigns secured.
- Revenue declined 4% year-over-year due to a postponed order worth INR10 million, impacting Q1 results.
- EBITDA margin for CDMO segment dropped to 6.3% from 17.9% due to revenue deferment and foreign exchange loss.
- Net loss before tax of INR512 million, with a foreign exchange impact of INR117.3 million from USD/CHF fluctuations.
- French drug product subsidiary faces market challenges, with slower-than-expected progress toward breakeven.
- High debt levels persist, with finance costs around INR370 million per quarter, though refinancing plans are underway.
Good evening, ladies and gentlemen. I'm Akash, moderator for the conference call. Welcome to Dishman Carbogen Amcis Limited Q1 FY27 Earnings Conference Call. We have with us today Mr. Stephan Fritschi, Chief Executive Officer, Carbogen Amcis; Mr. Harshil Dalal, Global Chief Financial Officer; Mr. Paolo Armanino, Chief Operating Officer, India; Ms. Angela Ameriks, Chief Commercial Officer; and Mr. Krishna Patel, EY. (Operator Instructions) Please note, this conference is being recorded.
I would now like to hand over the floor to Mr. Stephan Fritschi. Thank you, and over to you, sir.
Okay. Thank you very much. Welcome, everybody, to today's investor call to talk about the Q1 '26/'27 financial results. As you heard, this is Stephan Fritschi speaking. I'm the CEO of Carbogen Amcis. Before we go into the financials, I would like to give some brief operational update about Carbogen Amcis, followed by Paolo's update on different Carbogen Amcis operations.
But let
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
